Latest News
AMR Clinical acquires ClinOhio Research Services
30 June 2026 - AMR Clinical, a US-based, multi-site research company, said on Monday it has acquired ClinOhio Research Services (ClinOhio), a multi-therapeutic research site founded in 2017 and based in Columbus, Ohio.AMR says that the acquisition ex...
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
30 June 2026 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company involved in the treatment and prevention of cancer, announced on Monday that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number ...
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has validated the Mark...
Viatris announces VR-205 Phase 3 Study results in Japanese adults with primary immunoglobulin A nephropathy
30 June 2026 - Viatris Inc. (NASDAQ: VTRS), a US-based global healthcare company, announced on Monday positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefe...
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
30 June 2026 - Grünenthal, a Germany-based pharmaceutical company, announced on Monday that the company has successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.The company says that in the...